RYTM Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Rhythm Pharmaceuticals Inc (RYTM) following the 2026 Q2 hedge fund 13F filings?

As of today, RYTM has moved -3.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.2% for the XLV sector ETF — an outperformance of -5.2%. Since the quarter end (June 30, 2026), RYTM gained +0.9% vs +7.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Rhythm Pharmaceuticals Inc (RYTM)

301 + Investors. Track Smart Money conviction in RYTM. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — RYTM

Based on 303 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q

For 8 consecutive quarters, more hedge funds added RYTM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

303 hedge funds hold RYTM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +32% more funds vs a year ago

fund count last 6Q

+74 new funds entered over the past year (+32% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 54% buying

174 buying148 selling

Last quarter: 174 funds bought or added vs 148 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~66 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 55 → 57 → 64 → 66. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 26% medium ■ 30% new

135 out of 303 hedge funds have held RYTM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +35% but shares only +17% — price-driven

Value

+35%

+16%

Last quarter: the total dollar value of institutional holdings rose +35%, but actual share count only changed +17%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

33 → 55 → 57 → 64 → 66 new funds/Q

New funds entering each quarter: 55 → 57 → 64 → 66. A growing number of institutions are discovering RYTM each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 52% veterans vs 33% newcomers

■ 52% veterans ■ 15% 1-2yr ■ 33% new

Entry-cohort mix of 309 holders: 161 (52%) are 2+ year veterans, 46 entered 1–2 years ago, and 102 (33%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 43% AUM from top-100 funds

43% from top-100 AUM funds

58 of 303 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in RYTM. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.0

out of 10

Moderate Exit Risk

Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	301	286	5.24%
13F Shares	77M	72M	6.94%
Total Value	$8.25B	$6.14B	34.37%
New Positions	65	64	+1
Increased Positions	106	101	+5
Closed Positions	50	53	-3
Reduced Positions	97	88	+9
Total Calls	3	3	-
Total Puts	3	3	-
PUT/CALL Ratio	1.0	1.0	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

301

286

5.24%

13F Shares

77M

72M

6.94%

Total Value

$8.25B

$6.14B

34.37%

New Positions

Increased Positions

106

101

Closed Positions

-3

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

1.0

Neutral

Institutional Holders (2026 Q2)

301 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RYTM. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 RYTM holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Checkpoint Capital L.P.	33.79%	1,186,000	$131.7M
2	NEXTBio Capital Management LP	6.73%	131,758	$14.6M
3	Ra Capital Management, L.P.	6.43%	6,666,837	$740.2M
4	Perceptive Advisors LLC	4.31%	2,586,295	$287.2M
5	Nan Fung Group Holdings Ltd	4.15%	49,120	$5.5M
6	Rock Springs Capital Management LP	3.75%	692,598	$76.9M
7	Silverarc Capital Management, LLC	3.59%	311,461	$34.6M
8	Baker BROS. Advisors LP	3.12%	5,604,483	$622.3M
9	Siren, L.L.C.	2.55%	1,136,275	$126.2M
10	Integral Health Asset Management, LLC	2.41%	550,000	$61.1M
11	Sofinnova Investments, Inc.	2.34%	408,027	$45.3M
12	Exome Asset Management LLC	2.21%	32,209	$3.6M
13	First Turn Management, LLC	1.83%	154,018	$17.1M
14	Braidwell LP	1.57%	381,128	$42.3M
15	Opaleye Management Inc.	1.23%	122,500	$13.6M
16	Sphera Funds Management LTD.	1.16%	80,400	$8.9M
17	Blue Owl Capital Holdings LP	1.03%	61,455	$6.8M
18	PFM Health Sciences, LP	0.97%	101,550	$11.3M
19	AlphaCentric Advisors LLC	0.89%	9,449	$1.0M
20	Nicholas Investment Partners, LP	0.87%	139,270	$15.5M
21	Westfield Capital Management Co LP	0.80%	2,208,595	$245.2M
22	Atom Investors LP	0.73%	73,465	$8.2M
23	ADAR1 Capital Management, LLC	0.69%	136,158	$15.1M
24	Orbimed Advisors LLC	0.66%	322,900	$35.9M
25	Logos Global Management LP	0.60%	125,000	$13.9M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Rhythm Pharmaceuticals Inc (RYTM)

What does the Smart Money Trend signal show for RYTM?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added RYTM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RYTM?

Slight buying edge — 54% buying: Last quarter: 174 funds bought or added vs 148 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RYTM holders?

Elite ownership — 43% AUM from top-100 funds: 58 of 303 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in RYTM. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held RYTM?

45% of holders stayed for 2+ years: 135 out of 303 hedge funds have held RYTM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Rhythm Pharmaceuticals Inc (RYTM) following the 2026 Q2 hedge fund 13F filings?

As of today, RYTM has moved -3.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.2% for the XLV sector ETF — an outperformance of -5.2%. Since the quarter end (June 30, 2026), RYTM has gained +0.9% vs +7.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Rhythm Pharmaceuticals Inc (RYTM)

Smart Money Signals — RYTM

Buying streak — 8 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +32% more funds vs a year ago

Slight buying edge — 54% buying

Steady new buyers — ~66 new funds per quarter

45% of holders stayed for 2+ years

Value +35% but shares only +17% — price-driven

Growing discovery — still being found

Veteran-anchored — 52% veterans vs 33% newcomers

Elite ownership — 43% AUM from top-100 funds

Institutional Sentiment Summary — RYTM

Hedge Fund Ownership: RYTM

Market Analysis: RYTM

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: RYTM

Is It Too Late to Buy Rhythm Pharmaceuticals Inc (RYTM) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: RYTM

Statistics: RYTM

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Rhythm Pharmaceuticals Inc (RYTM)

Welcome to 13Foresight!